Empiric Validation of Simulation Models for Estimating Glucose Meter Performance Criteria for Moderate Levels of Glycemic Control

2013 ◽  
Vol 15 (12) ◽  
pp. 996-1003 ◽  
Author(s):  
Brad S. Karon ◽  
James C. Boyd ◽  
George G. Klee
2010 ◽  
Vol 56 (7) ◽  
pp. 1091-1097 ◽  
Author(s):  
Brad S Karon ◽  
James C Boyd ◽  
George G Klee

Abstract Background: Glucose meter analytical performance criteria required for safe and effective management of patients on tight glycemic control (TGC) are not currently defined. We used simulation modeling to relate glucose meter performance characteristics to insulin dosing errors during TGC. Methods: We used 29 920 glucose values from patients on TGC at 1 institution to represent the expected distribution of glucose values during TGC, and we used 2 different simulation models to relate glucose meter analytical performance to insulin dosing error using these 29 920 initial glucose values and assuming 10%, 15%, or 20% total allowable error (TEa) criteria. Results: One-category insulin dosing errors were common under all error conditions. Two-category insulin dosing errors occurred more frequently when either 20% or 15% TEa was assumed compared with 10% total error. Dosing errors of 3 or more categories, those most likely to result in hypoglycemia and thus patient harm, occurred infrequently under all error conditions with the exception of 20% TEa. Conclusions: Glucose meter technologies that operate within a 15% total allowable error tolerance are unlikely to produce large (≥3-category) insulin dosing errors during TGC. Increasing performance to 10% TEa should reduce the frequency of 2-category insulin dosing errors, although additional studies are necessary to determine the clinical impact of such errors during TGC. Current criteria that allow 20% total allowable error in glucose meters may not be optimal for patient management during TGC.


Author(s):  
Felipe Martins de Oliveira ◽  
Luís Eduardo Procópio Calliari ◽  
Cecília Kauffman Rutenberg Feder ◽  
Maria Fernanda Ozorio de Almeida ◽  
Mariana Vilela Pereira ◽  
...  

Author(s):  
Sally McLaughlin ◽  
John S. Gero

The expertise of designers consists, primarily, of information about the relationship between goals or performance criteria and the attributes of the desired artifact that will result in performances that will satisfy these criteria. The designer like experts in other fields is typically better at applying the knowledge that constitutes his expertise than he is at articulating this knowledge. Generation and simulation models are discussed as a means of generating a set of designs for which the set of attributes defining these designs and the performance of these designs in terms of the criteria considered are explicitly defined. Pareto optimization is discussed as a means of structuring these designs on the basis of their performance. The induction algorithm ID3 is used as a means of inferring general statements about the nature of solutions which exhibit Pareto optimal performance in terms of a set of performance criteria. The rules inferred in building design domain are compared with those extracted using a heuristic based learning system.


2019 ◽  
Vol 14 (3) ◽  
pp. 513-518
Author(s):  
Andrew W. Lyon ◽  
Martha E. Lyon

Background: The objective of this study was to estimate the combinations of total bias and total imprecision required for devices to meet the Food and Drug Administration (FDA) specifications using Monte Carlo simulation rather than collection and analysis of experimental data. Methods: A model Gaussian distribution of true-glucose values was altered by adding bias and imprecision to create measured-glucose values affected by analytic error. The fraction of measured-glucose values that met the 2018 FDA criteria for blood glucose monitoring system (BGMS) or self-monitoring blood glucose (SMBG) devices was determined as a function of bias and imprecision. Results: The BGMS model determined that a maximum total imprecision of 6% was required with no bias, and with a total bias of +10 mg/dL the total imprecision allowed was reduced to 5% to achieve the 95% FDA performance expectation: 95% of results ≥75 mg/dL within ±12% and 95% of results <75 mg/dL within ±12 mg/dL. The SMBG model determined that a maximum total imprecision of 6% was required at no bias, and with a total bias of +10 mg/dL the total imprecision allowed was reduced to 4% to achieve the 98% FDA expectation: 98% of results ±75 mg/dL within ±15% and 98% of results <75 mg/dL within ±15 mg/dL. Conclusions: The 2018 FDA guidance criteria require strict conditions for glucose meter clinical trials to achieve <10 mg/dL total bias and total imprecision of <5%. Total imprecision and bias values assessed in models in this study represent the cumulative imprecision and bias errors for the glucose meters, the reference method, and preanalytic processes.


Author(s):  
Oleg A. Dianov ◽  
Vadim Maltsev ◽  
Elena Murina ◽  
Ilya Anfilov

Backgraund: Monitoring glycemic control in diabetes includes daily measurements of glucose levels at home, along with periodic monitoring of glycemia indicators on the whole. The main purpose of monitoring glycemic control is to accurately and authentically assess the glycemic level reached by each patient in order to ensure the glycemic goals achievement. Glycemic control assessment at a certain point in time is best achieved by self-monitoring the level of glucose in the blood, in that allows you to assess the presence of hyperglycemia and hypoglycemia to optimize the treatment strategy. Aims: Accuracy assessment of a medical device Portable blood glucose concentration meter with electrochemical single-use strip PKG-03 Satellite Express for glycemic control of children with diabetes. Materials and methods: In a group of children with diabetes (n = 105, age from 1 month to 17 years), simultaneously was taken capillary blood from one drop to assess the accuracy of glycemia levels on the "Satellite Express" glucose meter and on the laboratory glucose and lactate analyzer SUPER GL. Results: In a comparative analysis of 660 blood samples on the Clark error scale, was found that all deviations of glycemia values ​​obtained with the "Satellite Express" glucose meter were in zones A (99.7% - clinically correct values) and B (0.3% - safe deviations). The limits of permissible systematic error of measurements that meet the requirements of the National Standard of Russian Federation GOST R ISO 15197-2015 in terms of clause 6.3 System Accuracy amounted to 96.8% of deviations of glucose meter indications from reference values, which matches to areas of clinically correct and safe deviations. Conclusion: Using the "Satellite Express" glucose meter in clinical practice makes it possible to control glycemia qualitatively and it is safe for children aged from 1 month to 17 years.


2015 ◽  
Vol 32 (5) ◽  
pp. 578-595 ◽  
Author(s):  
Joana Hora ◽  
Pedro Campos

Sign in / Sign up

Export Citation Format

Share Document